Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis.
An P, Wei LL, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, Kuramitsu K, Lai M, Popov YV. · 2020
Read Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. by An P, Wei LL, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, Kuramitsu K, Lai M, Popov YV. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7217909.txt.
Introduction
An and co-authors show that danger signals from injured liver cell mitochondria directly switch on the cells that scar the liver. Their study appeared in Nature Communications. Mitochondria descend from ancient bacteria, so their parts look bacterial to the immune system. When liver cells die, these signals spill out. Their role in fibrosis was unknown before this work.
Using mouse strains that resist or accept liver scarring, the team traced the chain. Mitochondrial DNA was the main active ingredient in the spilled signals. The signals woke hepatic stellate cells, the liver's scar builders. Those cells then drove further scarring. Cleanup of dying cells by other cells controlled how much signal escaped. Liver macrophages, notably, did not respond to the same signals. The study names a new driver of liver fibrosis.
Catalog record
| CREATOR | An P, Wei LL, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, Kuramitsu K, Lai M, Popov YV. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis By Ping An, Lin-Lin Wei, Shuangshuang Zhao, Deanna Y Sverdlov, Kahini A Vaid, Makoto Miyamoto, Kaori Kuramitsu, Michelle Lai, Yury V Popov Published in: Nature Communications DOI: 10.1038/s41467-020-16092-0 ABSTRACT Abstract Due to their bacterial ancestry, many components of mitochondria share structural similarities with bacteria. Release of molecular danger signals from injured cell mitochondria (mitochondria-derived damage-associated molecular patterns, mito-DAMPs) triggers a potent inflammatory response, but their role in fibrosis is unknown. Using liver fibrosis resistant/susceptible mouse strain system, we demonstrate that mito-DAMPs released from injured hepatocyte mitochondria (with mtDNA as major active component) directly activate hepatic stellate cells, the fibrogenic cell in the liver, and drive liver scarring. The release of mito-DAMPs is controlled by efferocytosis of dying hepatocytes by phagocytic resident liver macrophages and infiltrating Gr-1(+) myeloid cells. Circulating mito-DAMPs are markedly increased in human patients with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis. Our study identifies specific pathway driving liver fibrosis, with important diagnostic and therapeutic implications. Targeting mito-DAMP release from hepatocytes and/or modulating the phagocytic function of macrophages represents a promising antifibrotic strategy. Subject terms: Mechanisms of disease, Liver diseases, Liver fibrosis, Non-alcoholic steatohepatitis, Experimental models of disease INTRODUCTION It is well known that individual patients with virtually any chronic liver disease demonstrate significant differences in the rate of fibrosis progression, ranging widely from 10 to 50 years until cirrhosis develops1. A similar phenomenon, the precise mechanism of which is poorly understood, has been reported in inbred mouse strains, where different genetic makeup determines susceptibility to liver fibrosis. This ranges from fibrosis resistance in A/J mice to high susceptibility in the BALB/c strain2,3. Understanding the cellular and molecular basis for susceptibility versus resistance to fibrosis/cirrhosis is critical to development of effective antifibrotic therapies, identification of patients who are likely to progress and most in need of antifibrotic treatment, and for stratification of patients in clinical trials4. Prior studies provide evidence that a complex interplay of genetic factors, and possibly epigenetic and environmental factors, might determine the wide variation in susceptibility to fibrosis among individuals. Using quantitative trait loci analysis, Hillebrandt et al.2 identified complement 5 as one of the susceptibility genes in inbred mice, and confirmed that a polymorphism in this gene correlates with fibrosis in human patients with chronic hepatitis C5. Another GWAS study in hepatitis C patients identified polymorphisms in the TLR4 (Toll-like receptor 4) gene as a determinant of fibrosis progression6. However, the precise cellular and molecular basis of varying individual susceptibility to fibrosis, as found in all chronic disease irrespective of etiology, remains poorly understood. Regardless of underlying etiology, the initiating event eventually leading to tissue fibrosis is cell injury and/or death. Sterile cell death and injury (e.g., hepatocytes in the liver) may lead to the release of intracellular molecules called damage-associated molecular patterns (DAMPs). These molecules are recognized by the innate immune system by pattern recognition receptors, often the same molecular sensors that detect pathogens. DAMPs are derived from different subcellular compartments, including mitochondria, which evolved from proteobacteria (engulfed several billions years ago by a eukaryotic cell and adapted as intracellular “endosymbionts”)7. Due to bacterial origin, many structural components of mitochondria (including its DNA) share significant similarities with bacteria and are considered a major source of highly immunogenic “mito-DAMPs” exposed by injured or dying cells8. The liver is extremely rich in mitochondria due to its critical metabolic function in the body, with each hepatocyte containing 1000–2000 mitochondria9. Particularly in the liver, mito-DAMPs released from injured hepatocytes may represent one of the most abundant and potent “danger signals” that trigger or perpetuate the innate immune response. However, whether hepatocyte-derived mito-DAMPs impact fibrogenesis in the liver disease is not known. The complexity of regulatory control of scarring is further increased by the fact that multiple hepatic cell lineages participate in the fibrotic response. While activated hepatic stellate cells/myofibroblasts (HSCs/MFs) are the ultimate fibrogenic effector cell directly responsible for laying down fibrillar collagens10, the critical paracrine contribution of macrophages11, hepatic progenitor cells/reactive cholangiocytes12, and endothelial cells13 in determining the pace of fibrosis progression is now increasingly recognized. Macrophages in particular have a central but complex role in regulating liver fibrosis14, exerting opposing roles during progressive and regression stages of liver fibrosis15. The mechanistic role of their phagocytic function of efferocytosis (the process of engulfment and removal of dead/dying cells by neighboring phagocytes), the main mechanism that limits inflammatory response to the “danger signals” emanating from damaged or dead cells, in regulating fibrotic outcomes remains obscure. In this study, we performed in-depth studies of recovery from sub-lethal acute livery injury using an inbred-resistant/-susceptible mouse strain model system in order to characterize and interrogate the pathophysiologic mechanism responsible for susceptibility to tissue fibrosis. We show that efficient efferocytosis (phagocytosis of injured/dead hepatocytes) by resident F4/80(+) liver macrophages and infiltrating Gr-1(+) myeloid cells prevents the release of hepatocyte-derived mito-DAMPs and is a critical determinant of resistance to hepatic fibrosis. Conversely, prolonged exposure to mito-DAMPs post injury due to inefficient efferocytosis of dead hepatocytes, or exogenous mito-DAMPs administration, is sufficient to trigger fibrogenic activation of HSCs in vivo and in vitro. Mitochondrial DNA (mtDNA), a major active component of mito-DAMPs, is elevated in the sera of non-alcoholic steatohepatitis (NASH) patients and particularly those with significant fibrosis. These findings represent the discovery of a novel regulatory pathway in hepatic fibrosis with important diagnostic and therapeutic implications. RESULTS Fibrosis-resistant/-susceptible inbred mouse strain model First, we characterized fibrosis susceptibility in three common inbred mouse strains (FVB, C57Bl/6, and BALB/c) subjected to chronic administration of hepatotoxin thioacetamide (TAA) for 6 weeks. FVB demonstrated resistance; BALB/c strain developed the most significant fibrosis; and C57Bl/6 mice showed intermediate susceptibility to liver fibrosis (Supplementary Fig. 1). Chronic hepatotoxin-induced fibrosis models are characterized by repetitive liver injury, which leads to gradual fibrosis progression over an extended period of time. We hypothesized that such dramatically divergent strain phenotypes might be determined by strain-specific differences in response to each acute insult. To test this, we established a model of recovery from a single sub-lethal dose of TAA, and compared the FVB, C57Bl/6, and BALB/c strains’ responses 1, 3, 5, and 8 days thereafter (Fig. 1a). Biochemical quantification of hepatic collagen revealed readily detectable progressive collagen deposition into BALB/c livers starting from day 3 and reaching maximum (142% above control group levels, p < 0.001) on day 8 post TAA. In contrast, both FVB and C57Bl/6 mice developed significantly less fibrosis, with maximum collagen levels reaching 77% and 88%, respectively, above their healthy controls (Fig. 1b). Upon histological examination, connective tissue deposits were readily detected by Sirius Red staining starting on day 8 in pericentral areas of BALB/c mice, but not of FVB or C57Bl/6 mice (Fig. 1d). The degree of hepatotoxin-induced injury was similar between all three strains studied, as measured by cumulative serum alanine aminotransferase (ALT) levels 12–96 h post TAA (“area under curve” analysis, Fig. 1c). Overall, based on data in this single-dose TAA injury model, we were able to recapitulate strain differences in susceptibility to fibrosis observed in the chronic TAA injury model (BALB/c > C57Bl6 > FVB, Supplementary Fig. 1). Importantly, similar results were obtained in FVB and BALB/c mice after